Drugs / iC9-CAR19
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03696784 | Mar 2019 → Aug 2025 overdue | B-cell non-Hodgkin lymphoma, immunoproliferative disorder, lymphatic system disorder | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iC9-CAR19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03696784 ↗ |
| Known as | ATLCAR.CD19 | “These modified ATLCAR.CD19 cells with the safety switch are referred to as iC9-CAR19 cells.” NCT03696784 ↗ |
| Action | Deplete | “seem to kill some of the tumor” NCT03696784 ↗ |
| Modality | Cell therapy | “chimeric antigen receptor T (CAR-T) cells” NCT03696784 ↗ |
| Route | Intravenous | “iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.” NCT03696784 ↗ |
| Target | CD19 | “targeting the CD19 antigen” NCT03696784 ↗ |